Pharmaceutical News

RSS

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacological therapy that shows promise for treating both solid-tumor cancers and hematologic malignancies.

1 Jun 2013

New drug for multiple myeloma could be available within next few months in Europe

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - today said the newest drug for treating multiple myeloma could be available to patients in Europe within the next few months.

1 Jun 2013

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Many glioblastoma patients treated with bevacizumab (Avastin-) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center.

1 Jun 2013

Depomed receives complete response letter for SEFELSA NDA

Depomed, Inc., a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration issued a complete response letter to the New Drug Application for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin to treat moderate to severe vasomotor symptoms due to menopause.

1 Jun 2013

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

A new study conducted in an ethnically diverse and predominantly low income population found that only one-fifth of rheumatoid arthritis patients had an overall adherence rate to prescribed oral medications at 80% or greater.

1 Jun 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

Vanda Pharmaceuticals announces submission of tasimelteon NDA to FDA

Vanda Pharmaceuticals Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for tasimelteon, a circadian regulator.

31 May 2013

First Edition: May 31, 2013

Today's early morning highlights from the major news organizations, including reports from the administration about the number of insurers that will be offering policies on the new online marketplaces.

31 May 2013

University of Strathclyde uses new imaging technique to track nanomedicines' effects on patients

A pioneering imaging technique to track the effects of next-generation nanomedicines on patients has been harnessed by a University of Strathclyde academic.

31 May 2013

Comprehensive analyses of the benefits and risks of NSAIDs

Charles H. Hennekens, MD, DrPH, the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University has published in the current issue of The Lancet the most comprehensive analyses of the benefits and risks of non-steroidal anti-inflammatory drugs, which include cyclo-oxygenase-2 inhibitors (coxibs).

31 May 2013

Extremely low doses of THC protect the brain from long-term cognitive damage

Though marijuana is a well-known recreational drug, extensive scientific research has been conducted on the therapeutic properties of marijuana in the last decade. Medical cannabis is often used by sufferers of chronic ailments, including cancer and post-traumatic stress disorder, to combat pain, insomnia, lack of appetite, and other symptoms.

31 May 2013

Innovative approach helps Virginia mount effective response to contaminated steroid crisis

An innovative "hybrid" surveillance strategy-highlighted by close cooperation between public health officials and clinical partners-helped Virginia mount an efficient and effective response to the ongoing outbreak of fungal meningitis and other infections, according to a report in the July/August issue of Journal of Public Health Management and Practice.

31 May 2013

Safer, more effective treatment option for ovarian cancer

A novel, targeted approach to chemotherapy that makes ovarian cancer cells more susceptible to the cytotoxic effects of an antitumor drug may offer a safer, more effective treatment option for this often deadly form of cancer.

31 May 2013

CREON Delayed-Release Capsules now available in US for patients with EPI

AbbVie announced that a new, higher-dose capsule of CREON (pancrelipase) Delayed-Release Capsules is commercially available in the United States. The U.S. Food and Drug Administration recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.

31 May 2013

FDA issues complete response letter to Endo's NDA for AVEED injection

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. announced today that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for Endo's long-acting testosterone undecanoate injection, AVEED, for men diagnosed with hypogonadism.

31 May 2013

FDA accepts Teva Pharmaceutical's sNDA for COPAXONE

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has accepted for review the company's supplemental new drug application for COPAXONE (glatiramer acetate injection) 40mg/ 1mL, a higher concentration dose of COPAXONE that offers a less frequent three times a week dosing regimen administered subcutaneously for patients with relapsing-remitting multiple sclerosis.

31 May 2013

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

30 May 2013

Researchers examine quality of information given by sales reps when promoting drugs to physicians

Dr. Genevi-ve Durrieu (from the Pharmaco-epidemiology team assessing the use of medication and the risks involved, Unit 1027 "Epidemiology and public health analyses: risks, chronic diseases and handicaps" - Inserm / Universit- Toulouse III - Paul Sabatier) led the French part of this study, the results of which are published in the Journal of General Internal Medicine. Within the framework of this international study, is France proving to be a model student?

30 May 2013

Injectable drugs used in TPN to be imported into US, says FDA

The U.S. Food and Drug Administration announced today that injectable drugs used in total parenteral nutrition in critical shortage will be imported into the United States and available to patients this week.

30 May 2013

Taking blood thinners before minor procedures safe for stroke patients

Many patients who have experienced strokes or mini strokes take blood thinners such as aspirin or warfarin (Coumadin) to reduce the risk of blood clots that can cause strokes.

30 May 2013

Pharmaceutical News

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

New drug for multiple myeloma could be available within next few months in Europe

Glioblastoma patients treated with bevacizumab have deterioration in neurocognitive function

Depomed receives complete response letter for SEFELSA NDA

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

GLYX-13 drug induces antidepressant results without street drug side effects

Vanda Pharmaceuticals announces submission of tasimelteon NDA to FDA

First Edition: May 31, 2013

University of Strathclyde uses new imaging technique to track nanomedicines' effects on patients

Comprehensive analyses of the benefits and risks of NSAIDs

Extremely low doses of THC protect the brain from long-term cognitive damage

Innovative approach helps Virginia mount effective response to contaminated steroid crisis

Safer, more effective treatment option for ovarian cancer

CREON Delayed-Release Capsules now available in US for patients with EPI

FDA issues complete response letter to Endo's NDA for AVEED injection

FDA accepts Teva Pharmaceutical's sNDA for COPAXONE

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Researchers examine quality of information given by sales reps when promoting drugs to physicians

Injectable drugs used in TPN to be imported into US, says FDA

Taking blood thinners before minor procedures safe for stroke patients

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News